27% of Consumers Are Stuck in the Loyalty Program Dark Ages. Can Hospitality Brands Get Them More Engaged?

In this episode of Say Yes to Travel, Host Sarah Dandashy invited Jon Wolfe, CEO of House Advantage on the show. The two discuss Wolfes’ background in the gaming industry, his move to owning businesses that center on a consumer loyalty program and understanding consumers’ habits. They later dive into the importance of using the current pandemic-associated challenges to see the opportunities for growth and new ways of doing things.

Wolfe says the data they collect in how people make buying decisions and understand consumer habits is essential in a loyalty program. But also, so is the security of that data. In establishing a cyber-security company, Wolfe says, “if our whole lives are immersed in technology as it has been during the pandemic,” cyber-security is a safe counter bet. “People wake up every day in other countries and spend their entire day looking for ways to plunder companies wealth.”

Wolfe doesn’t consider his work as a job but an extension of his passions and lifestyle. “I tend to invest, build where I live and spend all my time.” Wolfe attributes the success of his companies to viewing things from a consumer-first attitude and mentality.

Wolfe admits that “My companies don’t look related, but understanding lifestyle consumer habits, data, the laws around protecting data and the technology of protecting that data all fit.” Wolfe said there wasn’t a science in how things came together but more of seeing opportunities and going after solutions to needs surrounding a loyalty program.

“We look for things we have to offer during the shutdowns and challenges.” For example, Wolfe developed a new home unit called Hack Trap. With internet lifestyle technology connected to appliances, cameras, and monitors at home, they saw a need for home data protection. “With people working from home, and all of the technology, there was a convergence of needs that we’ve met,” says Wolfe. It’s essential to embrace new areas as a business. Wolfe believes, “There isn’t a concern that doesn’t have an opportunity tied to it. If you look at it the right way, you can exploit an opportunity. I’ve never seen a problem that doesn’t have an opportunity.”

More Stories Like This:

Is the Hotel of the Future Based on Digital Assets?

Rising Pressures in Travel Industry Could Impact Your Trip Security

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More